The three components represent different research targets within the growth-hormone signalling system. The diagram below is a conceptual research map, not a clinical protocol.
The CJC-1295 + Ipamorelin + GHRP-6 stack is a multi-component research combination built around peptides associated with growth-hormone-axis signalling. It should be described as a market/research combination, rather than as a standardized pharmaceutical formulation.
The most important nomenclature issue is CJC-1295. Commercial and research sources may use "CJC-1295" for either a DAC-containing long-acting analogue or a non-DAC form often described as Modified GRF(1-29). These are not interchangeable research materials.
Each component has its own molecular identity, research history and evidence profile. The three should not be treated as one molecule.
CJC-1295 is described as a synthetic analogue related to growth-hormone-releasing hormone. Research literature includes human studies of the DAC-containing form showing prolonged stimulation of GH and IGF-1.
Key terminology: DAC and No DAC are distinct research variants.Ipamorelin is a growth-hormone-releasing peptide investigated for its pharmacokinetic and pharmacodynamic effects in humans. Its research profile differs from that of CJC-1295.
Key terminology: GHS-R / ghrelin-receptor signalling.GHRP-6 is a synthetic growth-hormone-releasing peptide that has been studied in human volunteers and in combination with GHRH during provocative GH testing research.
Key terminology: GHRP-6 is not the same compound as ipamorelin.In a true multi-component vial, all components occupy the same final liquid volume. The volume is shared; the component masses are not added together before calculating an individual concentration.
There is no universally standardized CJC-1295 + Ipamorelin + GHRP-6 formulation. Commercial and research listings can differ in component ratios, total vial mass and, critically, the CJC-1295 variant.
CJC-1295 + Ipamorelin + GHRP-6, 3 mg of each component.
Other sellers may use unequal amounts of CJC-1295, Ipamorelin and GHRP-family peptides.
The three-component commercial blend should not be presented as an FDA-approved or clinically standardized pharmaceutical formulation.
For a multi-component vial, every component shares the same final liquid volume, but each component retains its own mass. Therefore, each peptide must be calculated separately.
The table below uses the illustrative 3 mg + 3 mg + 3 mg formulation. It is a mathematical reference only and does not establish an appropriate research or human-use volume.
| Component | Component Mass | 1 mL | 2 mL | 3 mL | 5 mL |
|---|---|---|---|---|---|
| CJC-1295 | 3 mg | 3 mg/mL | 1.5 mg/mL | 1 mg/mL | 0.6 mg/mL |
| Ipamorelin | 3 mg | 3 mg/mL | 1.5 mg/mL | 1 mg/mL | 0.6 mg/mL |
| GHRP-6 | 3 mg | 3 mg/mL | 1.5 mg/mL | 1 mg/mL | 0.6 mg/mL |
If each component contains 3 mg, changing the final volume changes each component's concentration by the same mathematical factor.
CJC-1295: 3 ÷ 1 = 3 mg/mL
Ipamorelin: 3 ÷ 1 = 3 mg/mL
GHRP-6: 3 ÷ 1 = 3 mg/mL
CJC-1295: 3 ÷ 2 = 1.5 mg/mL
Ipamorelin: 3 ÷ 2 = 1.5 mg/mL
GHRP-6: 3 ÷ 2 = 1.5 mg/mL
CJC-1295: 3 ÷ 5 = 0.6 mg/mL
Ipamorelin: 3 ÷ 5 = 0.6 mg/mL
GHRP-6: 3 ÷ 5 = 0.6 mg/mL
Human studies have evaluated CJC-1295 pharmacokinetics and pharmacodynamics. Published studies of the long-acting DAC form reported prolonged stimulation of GH and IGF-1 in healthy adults.
This does not establish equivalent evidence for every product sold under the CJC-1295 name, particularly where the DAC status is not specified.
Human pharmacokinetic/pharmacodynamic research has examined ipamorelin in healthy volunteers and documented a GH response after administration.
These studies provide component-level information, not evidence that an exact CJC-1295 + ipamorelin + GHRP-6 blend is safe or effective.
GHRP-6 has been evaluated in human research, including pharmacokinetic studies and studies examining GH responses.
GHRP-6 research should not be conflated with ipamorelin research. They are different peptides within the broader GHRP/GHS research family.
Evidence for CJC-1295, ipamorelin and GHRP-6 individually does not establish the efficacy or safety of the three together.
No controlled human study of the exact three-component CJC-1295 + ipamorelin + GHRP-6 formulation was identified in the literature reviewed for this page.
Importantly, human studies have shown that GHRH and GHRP-6 can produce strong GH responses when administered together. That finding is useful for understanding the biology of GHRH/GHRP signalling, but it does not prove that replacing the GHRH component with a particular CJC-1295 variant and adding ipamorelin creates a clinically validated three-component intervention.
Multiple human studies have investigated GHRH together with GHRP-6, including provocative testing for GH reserve.
This supports a mechanistic research rationale for studying complementary GHRH/GHRP pathways.
GHRH + GHRP-6 research is not equivalent to a study of CJC-1295 + ipamorelin + GHRP-6.
The exact molecules, ratios, pharmacokinetics, exposure profiles and safety characteristics must be evaluated independently.
CJC-1295 terminology requires special attention because "CJC-1295" is not sufficient by itself to identify the research material.
The DAC-containing form is associated with albumin binding and a prolonged pharmacokinetic profile. Human studies have specifically evaluated this long-acting form.
Research distinction: prolonged exposure profile.Market sources commonly use "CJC-1295 No DAC" to refer to Modified GRF(1-29). It should not automatically be treated as pharmacologically equivalent to CJC-1295 with DAC.
Research distinction: shorter-acting analogue terminology.The conceptual rationale is that CJC-1295 is associated with GHRH signalling while ipamorelin and GHRP-6 belong to the broader growth-hormone secretagogue/GHRP research class. Related human research shows that GHRH and GHRP-6 can interact strongly at the level of GH secretion.
However, a mechanistic rationale is not the same as a validated combination therapy. Adding a third secretagogue changes the experimental system and creates additional variables that must be studied directly.
For laboratory mathematical reference, the concentration of each component is calculated from its own mass and the final liquid volume. The same volume is used for every component because they occupy the same vial.
CJC-1295 = 1 mg/mL
Ipamorelin = 1 mg/mL
GHRP-6 = 1 mg/mL
CJC-1295 = 0.6 mg/mL
Ipamorelin = 0.6 mg/mL
GHRP-6 = 0.6 mg/mL
Use the BacScience Universal BAC Water Calculator for single-compound concentration calculations. For a multi-component vial, calculate each component separately using its own mass while applying the same final liquid volume.
Open the Universal BAC Water Calculator →Commercial listings can differ in total mass, component ratio and CJC-1295 terminology. A product name alone is insufficient to establish composition.
Individual-component studies cannot be combined mathematically to create evidence for the complete three-component blend.
Results from one formulation, route or experimental design should not automatically be transferred to another formulation.
Research availability or commercial sale does not establish FDA approval, therapeutic efficacy or clinical safety.
CJC-1295 and ipamorelin have been specifically discussed by FDA in the context of bulk substances considered for compounding, including concerns related to characterization, peptide impurities, immunogenicity and, for CJC-1295, reported serious adverse reactions such as increased heart rate and systemic vasodilatory reactions.
FDA documentation has also identified safety concerns relating to ipamorelin acetate and noted limited information for certain injectable routes.
For competitive athletes, CJC-1295 and ipamorelin are listed among prohibited growth-hormone-releasing factors/secretagogues under the World Anti-Doping Agency prohibited-list framework. GHRP-6 is also included in that category.
No. The combination appears in research and commercial contexts, but component ratios and the exact CJC-1295 variant can differ. A product should be evaluated from its actual label and lot documentation.
The individual components and related GHRH/GHRP combinations have research histories, but that evidence should not be presented as a controlled clinical trial of the exact three-component blend.
No. DAC and No DAC refer to materially different research forms and should be identified separately. The long-acting DAC form has a substantially different pharmacokinetic profile from the shorter- acting No DAC/Modified GRF terminology used in many research listings.
No. If the final volume is 3 mL, each peptide is 1 mg/mL. The combined mass is 9 mg, but the individual concentration of each component is calculated from that component's own mass.
Increasing the final volume decreases the concentration of every component proportionally, assuming the component masses remain fixed.
The universal calculator is primarily designed around single-compound concentration mathematics. A multi-component vial requires the same volume calculation to be performed independently for every component.
No. Related GHRH + GHRP-6 studies provide mechanistic context, but they do not establish the efficacy, safety or optimal formulation of CJC-1295 + Ipamorelin + GHRP-6.
This page should be reviewed periodically because research listings, regulatory positions, formulation terminology and available clinical evidence can change.